Introduction {#s1}
============

The link between immunosuppressive therapy and increased lymphoma risk is well established in patients who have undergone solid organ transplantation and in those with rheumatoid arthritis with or without methotrexate medication \[[@R01], [@R02]\]. Of the non-Hodgkin lymphomas that develop in patients who have received a solid organ transplantation or who are on methotrexate for rheumatoid arthritis, up to 80% and 28%, respectively, contain the Epstein-Barr virus (EBV) genome \[[@R03], [@R04]\]. It has been postulated that EBV-infected lymphocytes proliferate unchecked in the setting of impaired cell-mediated immunity, giving rise to lymphoma.

The increased risk of lymphoma in the setting of inflammatory bowel disease (IBD) has been associated with the use of immunomodulatory therapy such as azathioprine (AZA), 6-mercaptopurine (6-MP), and cyclosporine (CSA), and biologic therapies such as infliximab, a chimeric monoclonal antibody against human tumor necrosis factor alpha (TNF-α), in medically refractory and fistulizing Crohn's disease and moderate to severe ulcerative colitis \[[@R05]\]. Most IBD-related lymphomas develop at sites of active intestinal inflammation in patients with longstanding disease. Less commonly seen are EBV-positive lymphomas arising within a pouch after proctocolectomy with ileal pouch anal anastomosis (IPAA) \[[@R11]\].

Case Report {#s2}
===========

Twenty-five years before being diagnosed with lymphoma, a 73-year-old man developed hematochezia and was diagnosed with ulcerative pancolitis. The patient was previously treated with a brief trial of prednisone, but was subsequently maintained on balsalazide at a dose of 6,750 mg per day with good control of his symptoms, without diarrhea or rectal bleeding. Colonic biopsies 2 years ago showed histologic evidence of chronic colitis in his left colon and rectum. The patient was never treated with immune modulators or biologic agents for his ulcerative colitis. The patient also had longstanding polymyositis for the past 6 years, initially diagnosed on the basis of symptoms including proximal muscle weakness, a creatine kinase (CK) level greater than 10,000 U/L (reference range: 44 - 196 U/L), and a positive electromyography (EMG) study suggestive of an inflammatory myopathy. He had responded to high doses of steroids, and methotrexate was added several years ago with a gradual dose titration up to 20 mg weekly. The patient's inflammatory muscle disease had never been completely controlled; serial CK levels remained in the range of 1,500 - 2,000 U/L.

A few months prior to the current presentation, the patient developed dysphagia that was clinically felt to be a manifestation of polymyositis. The patient's blood pressure was 151/85 mm Hg, his heart rate was 70 beats per minute, and his body weight was 203 pounds with a BMI of 32.3 kg/m^2^. On physical examination, the patient had weakness in his lower extremities and some difficulty getting up out of a chair without the use of his hands. No lymphadenopathy was noted. Due to the suboptimal control of his polymyositis symptoms, mycophenolate mofetil (Cellcept) at a dose of 1,000 mg per day was initiated and methotrexate was stopped on April 27, 2016, approximately 70 days prior to his surveillance colonoscopy in an outside hospital.

Esophagogastroduodenoscopy (EGD) performed for his dysphagia revealed abnormal motility of the esophagus, compatible with presbyesophagus, and a small hiatal hernia. A 17-mm Savary-type dilator was introduced for empirical dilatation. No definitive stricture was noted. A surveillance colonoscopy revealed normal mucosa in the cecum, ascending colon, and transverse colon. The descending colon and sigmoid colon, however, were characterized by erythema, friability, and congestion. In addition, a polypoid, nodular area with a slight stricture was noted in the sigmoid colon at 50 cm. The rectum was endoscopically normal. Biopsies were taken from the descending colon and from the polypoid, nodular, strictured area in the sigmoid colon.

The sigmoid colon biopsy revealed a neoplasm comprised of a solid proliferation of large mononuclear cells with a high nucleus to cytoplasm (N/C) ratio, irregular nuclei, and distinct nucleoli ([Fig. 1a](#F1){ref-type="fig"}). Tumor cell nuclei approximated the size of normal macrophage nuclei and were more than twice the size of normal lymphocytes. The tumor cells expanded the lamina propria and pushed the crypts apart, focally infiltrating the crypt epithelium (not shown). There was focal necrosis within the tumor ([Fig. 1b](#F1){ref-type="fig"}). By immunohistochemistry, the tumor cells were diffusely positive for CD20 ([Fig. 1c](#F1){ref-type="fig"}), PAX5 ([Fig. 1d](#F1){ref-type="fig"}), and CD30 ([Fig. 1g](#F1){ref-type="fig"}), strongly positive for BCL2 and MUM1 (not shown), and variably reactive for BCL6 ([Fig. 1e](#F1){ref-type="fig"}). There was a high Ki67 labeling index (about 80-90%) ([Fig. 1f](#F1){ref-type="fig"}). Tumor cells were negative for CD3, CD5, CD10, cyclin D1, and SOX-11. The tumor cells were positive for EBV by *in situ* hybridization ([Fig. 1h](#F1){ref-type="fig"}). A similar atypical lymphoid infiltrate was noted in the lamina propria ([Fig. 2a](#F2){ref-type="fig"}) and crypt epithelium ([Fig. 2b](#F2){ref-type="fig"}) in the descending colon biopsy. In addition, the descending colon biopsy showed mildly active chronic colitis (not shown). The overall histology and immunophenotype supported a diagnosis of an EBV-positive diffuse large B-cell lymphoma (DLBCL), non-germinal center type, involving the descending and sigmoid colon and arising in a background of ulcerative colitis.

![Histologic features and immunophenotype of diffuse large B-cell lymphoma in biopsy from the sigmoid colon polyp. (a) Atypical mononuclear infiltration in the lamina propria of the colonic biopsy (hematoxylin & eosin stain, original magnification × 100). (b) Focal tumor necrosis (hematoxylin & eosin stain, original magnification × 100). (c) Immunoreactivity of CD20 in tumor cells (immunoperoxidase stain, original magnification × 100). (d) Immunoreactivity of PAX5 in tumor cells (immunoperoxidase stain, original magnification × 100). (e) Immunoreactivity of BCL6 in tumor cells (immunoperoxidase stain, original magnification × 100). (f) High Ki67 labeling index (up to 80-90%) (immunoperoxidase stain, original magnification × 200). (g) Immunoreactivity of CD30 in tumor cells (immunoperoxidase stain, original magnification × 100). (h) Many Epstein-Barr virus-infected tumor cells by *in situ* hybridization (chromogenic *in situ* hybridization, original magnification × 200).](gr-09-083-g001){#F1}

![Atypical mononuclear cells are present in the lamina propria and focally infiltrate the crypt epithelium (a: hematoxylin & eosin stain, original magnification × 100; b: hematoxylin & eosin stain, original magnification × 200).](gr-09-083-g002){#F2}

Staging positron emission tomography with computed tomography (PET-CT) revealed intense focal pathologic uptake in the colon corresponding to the patient's biopsied lymphoma in a background of generalized physiologic uptake. There were no additional sites of increased uptake. The patient is currently scheduled to receive six cycles of dose-adjusted rituximab, etoposide, prednisolone, oncovin, cyclophosphamide, and hydroxydaunorubicin (DA-R-EPOCH) chemotherapy.

Discussion {#s3}
==========

The risk of lymphoma in IBD has been associated with the use of immunomodulatory therapy such as AZA, 6-MP, and CSA, and the use of biologics such as infliximab, in medically refractory and fistulizing Crohn's disease and moderate to severe ulcerative colitis \[[@R05], [@R11]\]. Cases of EBV-positive lymphoma arising within a pouch after proctocolectomy with IPAA have also been reported \[[@R11]\].

Here we report a case of EBV-positive DLBCL involving the colon in a patient with ulcerative colitis, whose IBD symptoms were well controlled with balsalazide. The patient also had a history of polymyositis, which had been treated with long-term methotrexate. The tumorigenesis of EBV-positive DLBCL in this case may be related to the patient's old age (73 years), the long-term use of methotrexate, and IBD. It is arguable whether this represents an EBV-positive DLBCL of the elderly or EBV-positive methotrexate-associated DLBCL. EBV-positive DLBCL of the elderly, initially described in 2003, is a provisional entity in the 2008 World Health Organization classification system and is defined as an EBV-positive monoclonal large B-cell proliferation that occurs in patients greater than 50 years of age and in whom there is no known immune deficiency, history of transplantation, or history of lymphoma \[[@R12]\].

Our patient had a history of polymyositis treated with long-term methotrexate, which was stopped 70 days prior to his colonoscopy. Long-term low-dose methotrexate therapy has been described in association with an EBV-positive, CD30-positive large B-cell lymphoma in one patient with a polymyositis-like condition \[[@R02]\]. The patient responded well to oral prednisone and acyclovir without cytotoxic chemotherapy. Our case most likely represents an EBV-positive DLBCL related to methotrexate use. The manifestation of lymphoma in the colon may be related to the patient's ulcerative colitis, as DLBCL has been reported to be associated with chronic inflammation \[[@R16]\]. Furthermore, most IBD-related lymphomas develop at sites of active intestinal inflammation in patients with longstanding disease \[[@R05]\].

In summary, we report a case of EBV-positive DLBCL involving the colon in a background of longstanding ulcerative colitis in a patient with polymyositis, treated with long-term methotrexate. Recognition of this entity is clinically significant as it may show spontaneous remission after cessation of methotrexate \[[@R02], [@R04]\]. In cases without spontaneous remission, other therapeutic modalities, including cytotoxic chemotherapy, may be necessary.

Disclosure {#s4}
==========

None.

Grant Support {#s5}
=============

None.
